Skip to main content
OpenTrials
Completed

NCT Number: NCT03729206

Microcirculation in Patients With Leukemic Hyperleukocytosis

Hyperleukocytosis in patients with acute leukemia impacts rheology and microvascularization, leading to severe symptoms or even death. The investigators investigated whether blood stream alterations induced by hyperleukocytosis can be detected by sidestream dark-field imaging and whether they correlate with the grade of symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperleukocytic Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Universitätsklinikum Münster

Münster, 48149, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • acute leukemia
  • de-novo or relapsed stage
  • able to give consent

Exclusion criteria

  • severe oral mucositis
  • unable to give consent
  • pregnant women
  • patients hospitalized for psychiatric disease

Treatment and study plan

intravital microscopy

Diagnostic Test

intravital microscopy with sidestream dark-field imaging

Primary outcomes

  1. microvascular flow index (MFI) of sublingual microcirculation

    Time frame: 24 months

Sponsors and collaborators

Lead sponsor

University Hospital Muenster

Other

Registry information

Official study title

Visualization of Microcirculation in Patients With Leukemic Hyperleukocytosis

Important dates

Study start
2018
Primary completion
2020
Study completion
2021
First posted
Nov 2, 2018
Registry last updated
Nov 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.